P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2

• Xavier Leleu,
• Shinsuke Iida,
• C. Ola Landgren,
• Alexander Lesokhin,
• Eric Leip,
• Arthur Kudla,
• Gregory Finn,
• Lugui Qiu

Affiliations

Xavier Leleu

1 CHU de Poitiers, Hôpital de la Milétrie, Pôle Régional de Cancérologie, Poitiers, France

Shinsuke Iida

2 Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

C. Ola Landgren

3 Department of Medicine, University of Miami Health System, Miami, United States

Alexander Lesokhin

4 Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States

Eric Leip

5 Pfizer Inc, Cambridge, United States

Arthur Kudla

5 Pfizer Inc, Cambridge, United States

Gregory Finn

5 Pfizer Inc, Cambridge, United States

Lugui Qiu

6 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China